Drug Search Results
More Filters [+]

AG-011

Alternative Names: ag-011, ag011, ag 011
Latest Update: 2009-09-10
Latest Update Note: Clinical Trial Update

Product Description

engineered Lactococcus lactis secreting human IL-10

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: ActoGeniX N.V.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AG-011

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Colitis, Ulcerative

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2008-000967-40

P2

Active, not recruiting

Colitis, Ulcerative

2009-10-14

AG011-MDUC-201

P2

Completed

Colitis, Ulcerative

2009-09-01

Recent News Events

Date

Type

Title